Liang Cao

Liang Cao

Auto-generated profile, based on publicly available information

Liang Cao

Molecular Targets Core, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RHRaffit Hassan
Raffit Hassan
MBMarcus Butler
Marcus Butler
RORoisin O'cearbhaill
Roisin O'cearbhaill
DODavid Y. Oh
David Y. Oh
MJMelissa Johnson
Melissa Johnson
DHDavid S. Hong
David S. Hong
The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors. The primary objectives were to evaluate safety and determine the recommended phase 2 dose (RP2D). Secondary objectives included efficacy. Thirty-two patients received gavo-cel at increasing doses either as a single agent (n = 3) or after lymphodepletion (LD,n = 29). Dose-limiting toxicities of grade 3 pneumonitis and grade 5 bronchioalveolar hemorrhage were noted. The RP2D was determined as 1 × 108cells per m2after LD. Grade 3 or higher pneumonitis was seen in 16% of all patients and in none at the RP2D; grade 3 or higher cytokine release syndrome occurred in 25% of all patients and in 15% at the RP2D. In 30 evaluable patients, the overall response rate and disease control rate were 20% (13% confirmed) and 77%, respectively, and the 6-month overall survival rate was 70%. Gavo-cel warrants further study in patients with mesothelin-expressing cancers given its encouraging anti-tumor activity, but it may have a narrow therapeutic window. ClinicalTrials.gov identifier:NCT03907852.

1 July 2010 in Cancer
Verified
Journal Article
Open access
PDF file
PZPaolo Andrea Zucali
Paolo Andrea Zucali
IPIacopo Petrini
Iacopo Petrini
ELElena Lorenzi
Elena Lorenzi
MSMaría Merino Salvador
María Merino Salvador
LCLiang Cao
Liang Cao
GGGiuseppe Giaccone
Giuseppe Giaccone
BACKGROUND: Thymic malignancies are rare tumors. The insulin‐like growth factor‐1 (IGF‐1)/IGF‐1 receptor (IGF‐1R) system is involved in the development of the thymus. IGF‐1R expression in thymic epithelial malignancies is unknown.METHODS: The authors investigated the expression of IGF‐1R and phosphorylated AKT serine 473 (p‐AKT) by using immunohistochemistry and examined the clinicopathologic correlations in a retrospective, single‐institution surgical series of 132 patients with thymic epithelial malignancies.RESULTS: Earlier disease stage, less aggressive histologic types, and complete resection were significant positive prognostic factors for disease‐related survival and progression‐free survival, and being a woman was a better prognostic factor for disease‐related survival. IGF‐1R and p‐AKT protein levels were expressed in 20% and 36% of thymic tumors, respectively. Both markers were expressed more commonly in recurrent disease than in primary tumors, in more aggressive subtypes, and in more advanced disease stages. There was a trend toward better survival and progression‐free survival in patients who were negative for IGF‐1R or p‐AKT expression in the whole series. When only the 91 primary tumors, IGF1R expression was associated with worse progression‐free survival (P < .001).CONCLUSIONS: The current retrospective analysis demonstrated that disease stage, tumor histology, sex, and resection type were major prognostic factors in the survival of patients with thymic malignancies. The expression levels of IGF‐1R and p‐AKT in thymic tumors suggested that IGF‐1R is a potential target for treatment. Cancer 2010. Published 2010 by the American Cancer Society.

1 September 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AAAndrea Apolo
Andrea Apolo
DGDaniel Girardi
Daniel Girardi
SNScot A. Niglio
Scot A. Niglio
RNRosa Nadal
Rosa Nadal
AKAndre R. Kydd
Andre R. Kydd
AMAmir Mortazavi
Amir Mortazavi
PURPOSE: Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare genitourinary (GU) tumors in a dose-escalation phase I study. We report the final data analysis of the safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the phase I patients and seven expansion cohorts. METHODS: This is an investigator-initiated, multicenter, phase I trial. CaboNivo doublet expansion cohorts included (1) mUC, (2) mRCC, and (3) adenocarcinoma of the bladder/urachal; CaboNivoIpi triplet expansion cohorts included (1) mUC, (2) mRCC, (3) penile cancer, and (4) squamous cell carcinoma of the bladder and other rare GU tumors (ClinicalTrials.gov identifier: NCT02496208 ). RESULTS: The study enrolled 120 patients treated with CaboNivo (n = 64) or CaboNivoIpi (n = 56), with a median follow-up of 49.2 months. In 108 evaluable patients (CaboNivo n = 59; CaboNivoIpi n = 49), the ORR was 38% (complete response rate 11%) and the median duration of response was 20 months. The ORR was 42.4% for mUC, 62.5% for mRCC (n = 16), 85.7% for squamous cell carcinoma of the bladder (n = 7), 44.4% for penile cancer (n = 9), and 50.0% for renal medullary carcinoma (n = 2). Grade ≥ 3 treatment-related adverse events occurred in 84% of CaboNivo patients and 80% of CaboNivoIpi patients. CONCLUSION: CaboNivo and CaboNivoIpi demonstrated clinical activity and safety in patients with multiple GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of the bladder, renal medullary carcinoma, and penile cancer.

1 November 2023
Verified
Journal Article
Closed access
Shao LiShao Li
Shao Li
BWBoyang Wang
Boyang Wang
LCLiang Cao
Liang Cao
LXLi-Hao Xiao
Li-Hao Xiao
PCPan Chen
Pan Chen
WXWei Xiao
Wei Xiao

6 January 2015 in Chromatographia
Verified
Journal Article
Closed access
PDF file
MJMiao Miao Jin
Miao Miao Jin
GSGeng Shen Song
Geng Shen Song
YDYing Feng Du
Ying Feng Du
LCLiang Cao
Liang Cao
HXHui Jun Xu
Hui Jun Xu
LZLan Tong Zhang
Lan Tong Zhang

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
AZA. Zimmer
A. Zimmer
CPCody Peer
Cody Peer
LCL. Cao
L. Cao
EKE. Kohn
E. Kohn
SLStan Lipkowitz
Stan Lipkowitz
JLJ-M. Lee
J-M. Lee
Background: Recent data showed a PARP inhibitor, O and a VEGFR1-3 inhibitor, C together are clinically superior to O alone in recurrent platinum-sensitive ovarian cancer (OvCa). We hypothesized reduced VEGF signaling by C and DNA damage by O may complement anti-tumor activity of immune checkpoint blockade, D. We previously reported the safety data and RP2D of D in combination with O or C. We now report RP2D and PK/PD data of the D+O+C therapy (NCT02484404).